Recent studies have shown that CDK10 is a potential tumor suppressor in breast cancers, and CDK10/Ets2/c-RAF signaling has been demonstrated as an important determinant of breast cancer resistance to endocrine therapy [43]. Here, ETS2 is linked to breast cancer.